RNN News Alert Rexahn Pharmaceuticals (RNN) 0.75 02/13/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 13, 2015 at 10:55 PM

Rexahn Pharmaceuticals (RNN) 0.75 $RNN

17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)

Rexahn Pharmaceuticals Announces the Publication of Preclinical Data for Supinoxin(TM) (RX-5902) Demonstrating Mechanism of Action
GlobeNewswire - Mon Feb 09, 8:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the release of an online publication describing preclinical results for Supinoxin(TM) (RX-5902) in the peer reviewed medical journal, Journal of Cellular Biochemistry, in an article titled, "A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl] piperazine (RX-5902), Interferes with β-Catenin Function through Y593 phospho-p68 RNA Helicase." The article was coauthored by Dr. Zhi-Ren Liu of the Department of Biology, at Georgia State University, and Rexahn scientists.
RNN: 0.75 (+0.01)

Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer
GlobeNewswire - Wed Feb 04, 8:10AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the appointment of Ely Benaim, M.D. as Chief Medical Officer. In this role, Dr. Benaim will be responsible for leading Rexahn's clinical development programs, and providing strategic and clinical guidance for the Company.
RNN: 0.75 (+0.01)

Rexahn Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, PhD, the Company's Chief Executive Officer, will present a company update at the 17 Annual BIO CEO & Investor Conference being held in New York City, NY. The presentation will be on Tuesday, February 10, 2015 at 9:00am EST. An audio webcast and presentation for this conference will be available on the Company's website at www.rexahn.com in the Investor Relations section under 'Events and Presentations'.
RNN: 0.75 (+0.01)

Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 90.70 (+0.93), RNN: 0.75 (+0.01), NBIX: 37.22 (+0.27), ACHN: 10.89 (-0.20), ARRY: 8.05 (+0.08)

Rexahn Pharmaceuticals Down 5.3%, Shares Slide into the Red (RNN)
Comtex SmarTrend(R) - Thu Jan 15, 12:39PM CST
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's worst performing penny stocks, down 5.3% to $0.77 on 1.5x average daily volume. Rexahn Pharmaceuticals has traded 1.8 million shares thus far today, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.6%) and underperformed the S&P 500 (-5.3% to the S&P's -0.7%) during today's trading.
RNN: 0.75 (+0.01)

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off
Sharon di Stefano - Seeking Alpha - Tue Jan 13, 11:43AM CST
When peer-reviewed scientific articles publish, especially for investigational medicine, doctors and investors take notice. Few other accolades are held in such high esteem. In December, Rexahn Pharmaceuticals (NYSEMKT: RNN ) presented data in...
RNN: 0.75 (+0.01)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 12.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:51AM CST
Rexahn Pharmaceuticals (RNN) was a big mover last session with its shares rising almost 13% on the day.
RNN: 0.75 (+0.01), AMAG: 41.49 (+0.23)

Can The Uptrend Continue for Rexahn Pharmaceuticals (RNN)?

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rublev's Tennis Meet Boosts Inclusivity for Autism

Tennis Bridging Worlds in the Heart of Kazakhstan When Andrey Rublev, a powerhouse in the world of tennis, wields his racket for more than just a win, you know something special is brewing. During the Almaty Open ATP 250 tournament, he did exactly that, sharing the court not with rivals, but with ten spirited children from the Asyl Miras Autism Center. This heartwarming...

Tutoring America Champions Educational Equity with Grants

Bolstering Educational Support for Low-Income Students In a world where opportunities hang on the thread of education, Tutoring America stands as a beacon for those left behind. This nonprofit tackles the education gap head-on, aiming to uplift low-income kids before they hit high school turbulence. Frankly, what they're doing is more than just good work—it's laying the...

Firmable's Tech Intelligence: New Edge in B2B Sales

New Era for B2B Sales Teams Once again, the B2B sales landscape is getting a jolt—especially for those who’ve been fumbling in the dark pitching to prospects without any real idea of their tech environment. With the introduction of Firmable's Tech Intelligence, those blind days just got a lot brighter. By offering detailed insights into what technologies a company is...

New Wealth Firm Iron Shore Offers Tailored Financial Advising

A Fresh Take on Wealth Management This isn't your average wealth management spiel folks; it's something that's trying to give the old dusty models a shake-up. Kamar Plunkett and Shara Thomas have thrown their hats into the ring with Iron Shore Wealth Strategies. Anyone tuning into this financial soap opera would appreciate this pivot—because hey, when was the last time...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Florida Leaders Set Sights on Top 10 Economy by 2030

Florida's Ambitious Economic Goals When someone floats the idea of a state's economy cracking the top 10 globally by the year 2030, you've got to wonder if it's all sunshine and rainbows, or if there's some serious groundwork being laid. The Florida Chamber Foundation seems to think it's achievable. As the end of October rolls around, they're throwing the 2026 Future of...

Hyliion Faces Legal Whirlwind After Stock Tumbles 19.3%

Battered by Allegations: Hyliion in Legal Crosshairs Here's a hot mess Hyliion's found itself in. Amidst allegations of deception, the stock has dropped a hefty 19.3%. For anyone keeping tabs on this one, the legal eagles over at The Law Offices of Frank R. Cruz have swooped in, announcing a class action that's got all the trimmings of your classic securities mess. The...

Software Tax Hits Enterprises: Costly Control Concerns

Unanticipated Software Costs: Who's in Charge? Picture this: you're running a tech setup at a major corporation, but the software changes thrust upon you aren't anything you would've chosen freely. Yeah, that's about one in four dollars from your hot little budget spent on tweaks and adjustments you didn’t ask for. And it's not as glamorous as it sounds—more like a...

Dr. Schult Wins 2026 People Helping People Award

Dr. Deborah Schult: A Pioneer in Correctional Healthcare If you've been in the business of behavioral healthcare, particularly in correctional environments, then you know the name Dr. Deborah Schult is one that resonates with seasoned respect. This year's People Helping People Award from the American Board of Correctional Psychology shines a well-deserved spotlight on her...

AEVEX Faces Legal Scrutiny Amid Secondary Offering Stir

AEVEX on the Legal Hook: What's Going Down? Look, nobody likes bad news, especially when their pockets feel the pinch. AEVEX Corp. (NYSE: AVEX) kicked up quite the dust cloud when their stock plummeted after a secondary offering—dropping a whopping 16% at first glance, and then an extra seven in the blink of an eye. Timing Is Everything in the Stock Game Set the stage:...